So-Young shares tumble nearly 8% as Q2 revenue falls short of expectations

Published 15/08/2025, 12:18
 So-Young shares tumble nearly 8% as Q2 revenue falls short of expectations

BEIJING - On Friday, So-Young International Inc. (NASDAQ:SY) reported second quarter revenue that missed analyst expectations despite strong growth in its branded aesthetic centers.

The Chinese aesthetic treatment platform’s shares fell 7.85% in pre-market trading after the release.

The company reported second quarter revenue of RMB378.7 million ($52.9 million), down 7% YoY and well below the analyst consensus of RMB358.05 million. So-Young posted a non-GAAP net loss of RMB30.5 million ($4.3 million), compared to a non-GAAP net income of RMB22.2 million in the same period last year. However, its adjusted loss per share of RMB0.05 was better than the analyst estimate of RMB0.18 loss per share.

While overall revenue declined, So-Young’s aesthetic treatment services segment saw explosive growth, surging 426.1% YoY to RMB144.4 million ($20.2 million), exceeding the high end of the company’s guidance. This marked the first time branded aesthetic centers became the company’s largest revenue contributor.

"During the second quarter, our branded aesthetic centers became the largest contributor to revenue for the first time, a significant milestone in our transformation strategy," said Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young. "With 29 aesthetic centers now in operation across China, we have solidified our position as the country’s leading light medical aesthetics brand."

The company’s traditional information and reservation services revenue fell 35.6% to RMB135.2 million as fewer medical service providers subscribed to platform services. Sales of medical products also declined 28.1% to RMB76 million.

For the third quarter, So-Young expects aesthetic treatment services revenue between RMB150 million and RMB170 million, representing 230.5% to 274.6% growth from the same period in 2024.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.